Centessa Pharmaceuticals Director's Share Options Cancelled in Eli Lilly Acquisition

This Form 4 filing reports that Carol Stuckley, a director of Centessa Pharmaceuticals plc, had all her share options cancelled on June 24, 2026, as a result of Eli Lilly and Company's acquisition of Centessa. The acquisition was completed through a scheme of arrangement under UK law, with Eli Lilly's subsidiary LDH XV Corporation acquiring all outstanding ordinary shares. As part of the transaction, all outstanding share options were automatically cancelled and converted into cash payments and contingent value rights. Stuckley held five different share option grants totaling 392,474 options with exercise prices ranging from $4.87 to $12.43 per share, all of which were disposed of in the acquisition. The options were converted into cash payments based on the $38.00 per share acquisition price minus exercise prices, plus contingent value rights for potential additional payments up to $9.00 per share based on milestone achievements.